Dexchlorpheniramine-phenylephrine has been assigned to category C by the FDA. Animal studies have not been reported. There are no controlled data in human pregnancy. Dexchlorpheniramine-phenylephrine is only recommended for use during pregnancy when benefit outweighs risk.

Antihistamine exposure during the last two weeks of pregnancy has been associated with general and retrolental fibroplasia in premature infants.

See references

Dexchlorpheniramine is excreted into human milk. Side effects of antihistamine use have been described as a higher risk in infants, newborns, and premature babies than in the general population. The manufacturer recommends that due to the potential for serious adverse reactions in the nursing infant, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Small amounts of phenylephrine are secreted in breast milk. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

See references